Imperial Oil Limited Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B). The key difference: Imperial Oil Limited Common Stock is far larger — about 2.5× Roivant Sciences Ltd. Common Shares's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals.
| IMO | ROIV | |
|---|---|---|
Market Cap | $62.22B | $24.99B |
Volume | 560,544 | 4,711,562 |
Sector | Energy | Health |
52-Week High | $138.33 | $41.81 |
52-Week Low | $83.72 | $16.99 |
Enterprise Value | $63.13B | $21.25B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 3 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →